Due Diligence

Increase investors’ evaluation in a competitive market

Due Diligence is critical before dedicating precious time and resources to a research project that appears to hold commercial promise. Due Diligence is typically performed by investors but can, and should, be conducted by sponsors. Doing so increases their chances of financing success, partnering, mergers and acquisitions (M&As), and product licensing. For companies developing multiple products, Due Diligence can also inform and assist in deciding which products to budget for as part of portfolio management.

What is Due Diligence in clinical research?

Sponsors request third-party Due Diligence involving R&D assessments to increase investors’ evaluation in the current competitive market. Due Diligence is a systematic way to analyze and mitigate risk from a business or investment decision.

  • Clinical Due Diligence involves examining the disease selected based on the product MOA, the clinical plan, and Ph 1 & 2 synopses, including the patient selection and the inclusion/exclusion criteria. The sponsor’s proposed clinical plan and study design are benchmarked against the competition.
  • Regulatory Due Diligence involves understanding the product and the therapeutic areas to evaluate the sponsor’s regulatory strategy completeness and risks.

Due Diligence support funding and decision-making

Thoughtful and well-conducted Due Diligence saves considerable costs and shortens the new drug’s time-to-market.

Investigating the best path when transitioning the product from no-clinical to clinical requires comprehensive analysis, industry experience, and an in-depth understanding of the many factors that impact success.

An analysis of the product’s development, including its potential to achieve the expected goals, requires a solid knowledge of the processes and anticipated challenges. Due Diligence supports Investors’ and Sponsors’ decision-making.


We serve:

  • Biotech managers to make informed decisions
  • Venture Capitalists with comprehensive Due Diligence on the strategic and operational realities of the target
  • Sponsors developing drugs for rare diseases face unique challenges in the product lifecycle

Pin It on Pinterest